LB Pharmaceuticals Inc (LBRX) Stock Forecast
LBRX analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.64 / 5 from 11 analysts
- Price target
- $58.00 average of analyst targets
- Upside to target
- +57.9% from the latest close
- Next earnings
- November 5, 2026 EPS estimate $-1.61
- 52-week range
- $14.61 – $49.48
LBRX analyst ratings
11 analystsNumber of analysts at each rating.
LBRX price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
LBRX earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$1.52 | −$1.74 | −$1.07 | −$0.61 | −149.2% | 8 |
| Current fiscal year (2026) | −$5.47 | −$5.93 | −$4.63 | −$3.13 | −74.9% | 9 |
| Next fiscal year (2027) | −$5.13 | −$6.41 | −$4.14 | −$5.47 | +6.2% | 9 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
LBRX revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 9 |
| Current fiscal year (2026) | $0 | $0 | $0 | 0.0% | 10 |
| Next fiscal year (2027) | $0 | $0 | $0 | 0.0% | 10 |
LBRX EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
LBRX EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.93 | −$1.57 | −$1.56 | −$1.59 | −$1.52 | +63.4% | 0 up · 0 down |
| Current fiscal year (2026) | −$3.45 | −$5.56 | −$5.54 | −$5.60 | −$5.47 | +58.6% | 0 up · 0 down |
| Next fiscal year (2027) | −$4.41 | −$4.95 | −$5.04 | −$4.99 | −$5.13 | +16.4% | 0 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
LBRX earnings surprises
Reported EPS vs the consensus estimate for the last 5 quarters; LBRX beat in 1 of 5.
What analysts expect from LBRX
11 analysts cover LB Pharmaceuticals; their consensus rating is strong buy (4.64 on a 1–5 scale, where 5 is a strong buy). The average price target is $58.00, 57.9% above the latest close of $36.74. Analysts expect earnings of −$5.47 per share for 2026, −74.9% from a year earlier. For 2027 the average estimate is −$5.13 per share. LB Pharmaceuticals beat the EPS estimate in 1 of the last 5 quarters.
Related: LBRX income statement, LBRX key metrics, LBRX chart. See the LBRX stock overview for the latest quote and news.
LBRX forecast FAQ
What is LB Pharmaceuticals's price target?
The average analyst price target for LB Pharmaceuticals is $58.00, 57.9% above the latest close of $36.74.
Is LB Pharmaceuticals a buy, hold or sell?
Of 11 analysts covering LB Pharmaceuticals, 8 rate it a strong buy, 2 a buy, 1 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is LB Pharmaceuticals's EPS forecast?
Analysts forecast −$5.47 per share for 2026 (range −$5.93 to −$4.63); for 2027 the estimate is −$5.13.
When does LB Pharmaceuticals report earnings?
LB Pharmaceuticals is expected to report results for the quarter ending September 30, 2026 on November 5, 2026; the EPS estimate is $-1.61.
Does LB Pharmaceuticals usually beat earnings estimates?
LB Pharmaceuticals reported EPS at or above the analyst estimate in 1 of the last 5 quarters.